SBIR-STTR Award

We describe a novel fractionation and concentration system for high throughput analysis of low abundance polypetides in serum samples by matrix-assisted laser desoption ionization (MALDI) mass spectrometry (MS). We propose to develop this polypeptide analysis system (PPAS) commercially for the rapid and reproducible purification, fractionation and concentration of low abundance polypeptides and low molecular weight proteins from blood serum. The PPAS system consists of a series of thin layers between sample reservoirs and analyte capture sites on hydrophobia capture slides. The polypeptide analytes pass through the thin layers sequentially where separation, fractionation, concentration occur. The fractionated and concentrated polypeptides are captured on the hydrophobic capture slides, each that has a different affinity for hydrophobic polypeptides. Following analyte capture, the slides can be washed free of interfering salts or other molecules that may suppress MALDI ionization of the analytes in a mass spectrometer. In the analysis step, a MALDI matix soluiton is applied directly to the samples on the capture slides and the slides are inserted directly in a MALDI-mass spectrometer for high throughput analysis of the relative abundance of polypeptides of molecular weights from 1000 to 30,000 Daltons. A separation layer prior to the fractionation/capture slides is used to remove high-abundance proteins from the polypeptides prior to their fractionantion and capture. Polypeptides are driven through the separation and fractionation/capture layers by native protein electrophoresis, according to the native charge on the proteins at any selected pH of the sample. This mode of separation allows additional fractionation according to polypeptide isoelectric point. Concentration of analytes is achieved by providing for electrophoretically focusing the polypeptides into a small capture area on the fractionion/capture slides. Phase 1 of this research project includes testing, optimization and validation of a improved fractionation system in the PPAS for analysis of polypeptides in human serum. Subsequently Phase II of this research project would entail the design and construction of a beta prototype leading to commercialization of the system

High Throughput Fractionation and Concentration System for MALDI-MS This Small Business Innovative Research (SBIR) Phase II project aims to build upon the successful work completed in the Phase I feasibility study to optimize and construct a prototype system for the preparation of up to 96 serum samples in parallel for matrix assisted laser desorption ionization (MALDI) mass spectrometry (MS). This system, called the MALDIplex(tm) M5 Sample Prep Station, consists of a benchtop instrument, a graphical user interface (GUI), and single-use 96-well cartridges. The MALDIplex cartridges are specially designed to permit parallel vertical separation from each well through a series of stacked thin layer supports. The system permits integrated sample purification, fractionation, concentration, and desalting - all in a single, easy to use cartridge. Using this system, samples may be prepared simulaneously in less than 45 minutes. No other system offers the potential throughput and data quality achievable with this system. Phase II efforts will focus on the further development and optimization of quantitation and fractionation protocols, as well as improved system designs (for automation) and methods for protein identification from the cartridge surface. This innovative technology has the potential to play a key role in improving the understanding, diagnosis, prognosis, and treatment of complex disease such as cancer. If successful, the Phase II will result in an optimized sample preparation system ready for full scale manufacturing and commercialization in Phase III. 7. Project Narrative High Throughput Fractionation and Concentration System for MALDI-MS The search of novel drug targets and disease markers (biomarkers) using mass spectrometry holds tremendous potential for improving the understanding, diagnosis, prognosis, and treatment of disease. Many complex, life threatening diseases, such as cancer, require early diagnosis to maximize effective treatment. If successful, this Phase II research project will enable large scale, clinically-relevant biomarker discovery using mass spectrometry, which has the potential of revealing new, highly sensitive biomarkers for early disease diagnosis and to predict treatment response.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.